Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) and Obio, Inc., a corporation formed to pursue public and private funding for cancer research in Ohio, are working together to expand Biomoda’s lung cancer screening program for veterans into Ohio.
“We are also identifying sites for the upcoming Phase III trials, and Ohio is home to several world-class comprehensive cancer centers.”
“A strategic alliance with Obio gives Biomoda a presence in a state that is recognized as a leader in cancer research and treatment. Ohio’s leaders have established programs and funding to attract promising biomedical technologies to the state through innovative public initiatives that support both research and commercialization,” said John Cousins, President of Biomoda.
Biomoda currently is conducting clinical trials of its CyPath® lung cancer diagnostic assay, an inexpensive, noninvasive test designed to identify early-stage lung cancer by binding to cancer cells and causing them to fluoresce under ultraviolet light. Phase II trials have focused on military veterans who are at least 25 percent more likely to develop lung cancer and die from the disease.
Cousins said that Obio will help Biomoda launch a veterans screening program in Ohio, similar to ones completed in New Mexico and under consideration by the Nebraska Legislature. “We are also identifying sites for the upcoming Phase III trials, and Ohio is home to several world-class comprehensive cancer centers.”
Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. CyPath® is currently for investigational use only.
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients